Bayer announced the first patients have been enrolled in the initial trials for its OCEANIC clinical trial program, designed to explore the use of asundexian, an investigational oral Factor XIa, or FXIa, inhibitor, in patients with atrial fibrillation, or AF, and in patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, or TIA, a temporary period of symptoms similar to those of a stroke. Asundexian belongs to a potential new class of drugs being studied for thrombosis prevention.1-2 OCEANIC is one of the largest Phase III endeavors Bayer has ever undertaken.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BAYRY:
- Bluebell said to build Bayer stake in breakup push, Bloomberg reports
- Activist pushing for break-up at Bayer, Bloomberg reports
- Bayer downgraded to Equal Weight from Overweight at Morgan Stanley
- Dare Bioscience resumed with a Buy at Roth Capital
- Bayer downgraded to Neutral from Overweight at JPMorgan